Drugs / MOD-6031
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02692781 | Feb → Dec 2016 | obesity disorder | OPKO Health, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MOD-6031 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02692781 ↗ |
| Action | Activate | “is an agonist for both glucagon-like peptide-1 (GLP1) and glucagon (GCG) receptors.” NCT02692781 ↗ |
| Modality | Peptide | “The active moiety is a gastrointestinal neuropeptide” NCT02692781 ↗ |